Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …
[HTML][HTML] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
[HTML][HTML] Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review
R Feld, SS Sridhar, FA Shepherd, JA Mackay… - Journal of Thoracic …, 2006 - Elsevier
Introduction Inhibition of the epidermal growth factor receptor is a promising therapy in the
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …
treatment of non-small cell lung cancer (NSCLC). In this systematic review, we evaluated the …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
Phase II study of erlotinib in advanced non–small-cell lung cancer after failure of gefitinib
BC Cho, CK Im, MS Park, SK Kim, J Chang… - Journal of clinical …, 2007 - ascopubs.org
Purpose This study was designed to evaluate the efficacy and toxicity of erlotinib in patients
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …
with advanced non–small-cell lung cancer (NSCLC) who experienced disease progression …
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
MK Wong, AI Lo, B Lam, WK Lam, MS Ip… - Cancer chemotherapy and …, 2010 - Springer
Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer
Y Togashi, K Masago, S Fujita, Y Hatachi, A Fukuhara… - Lung cancer, 2011 - Elsevier
PURPOSE: The maximum tolerated dose (MTD) of erlotinib (150mg) is the approved daily
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …
dose. In contrast, the approved daily dose of gefitinib (250mg) is only one-third of its MTD …
[HTML][HTML] Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
DH Lee, SW Kim, C Suh, DH Yoon, EJ Yi, JS Lee - Annals of oncology, 2008 - Elsevier
Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …
相关搜索
- gefitinib and erlotinib adverse events
- gefitinib and erlotinib lung cancer
- gefitinib and erlotinib in patients
- gefitinib and erlotinib retrospective analysis
- erlotinib in patients previous chemotherapy
- erlotinib in patients randomized phase
- growth factor erlotinib in the treatment
- pooled analysis failure of gefitinib
- japanese patients daily erlotinib
- lung cancer adverse events
- erlotinib in patients adverse events
- erlotinib in patients lung cancer
- daily erlotinib adverse events
- retrospective analysis adverse events
- retrospective analysis lung cancer
- daily gefitinib adverse events